Market Research Logo

Polycystic Ovarian Syndrome - Pipeline Review, H1 2015

Polycystic Ovarian Syndrome - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Polycystic Ovarian Syndrome - Pipeline Review, H1 2015’, provides an overview of the Polycystic Ovarian Syndrome’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Polycystic Ovarian Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycystic Ovarian Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Polycystic Ovarian Syndrome
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Polycystic Ovarian Syndrome and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Polycystic Ovarian Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Polycystic Ovarian Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Polycystic Ovarian Syndrome
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Polycystic Ovarian Syndrome pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Polycystic Ovarian Syndrome Overview
Therapeutics Development
Pipeline Products for Polycystic Ovarian Syndrome - Overview
Pipeline Products for Polycystic Ovarian Syndrome - Comparative Analysis
Polycystic Ovarian Syndrome - Therapeutics under Development by Companies
Polycystic Ovarian Syndrome - Therapeutics under Investigation by Universities/Institutes
Polycystic Ovarian Syndrome - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Polycystic Ovarian Syndrome - Products under Development by Companies
Polycystic Ovarian Syndrome - Products under Investigation by Universities/Institutes
Polycystic Ovarian Syndrome - Companies Involved in Therapeutics Development
AstraZeneca PLC
Crinetics Pharmaceuticals, Inc.
EffRx Pharmaceuticals S.A.
Euroscreen S.A.
Merck KGaA
Neurocrine Biosciences, Inc.
Polycystic Ovarian Syndrome - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AZD-4901 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
choriogonadotropin alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ESN-364 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
metformin hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Antagonize GnRH for Endometriosis, Uterine Fibroids, and Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit KISS-1R for Polycystic Ovarian Syndrome - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit Plasminogen Activator Inhibitor-1 for Thromboembolic Disease, PCOS and Alopecia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptide for Metabolic Syndrome and Polycystic Ovarian Syndrome - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Polycystic Ovarian Syndrome - Recent Pipeline Updates
Polycystic Ovarian Syndrome - Dormant Projects
Polycystic Ovarian Syndrome - Product Development Milestones
Featured News & Press Releases
Dec 08, 2014: Euroscreen Announces Positive Completion of Phase I Trial of ESN364
Jun 10, 2014: EffRx Receives U.S. Orphan Drug Designation for EX404 for Treatment of Pediatric Polycystic Ovary Syndrome
Oct 01, 2013: EffRx Receives Prestigious EUR 5.9 Million FP7 Research Grant for the Development of EX404 for Polycystic Ovary Syndrome in Paediatric Populations
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Polycystic Ovarian Syndrome, H1 2015
Number of Products under Development for Polycystic Ovarian Syndrome - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Polycystic Ovarian Syndrome - Pipeline by AstraZeneca PLC, H1 2015
Polycystic Ovarian Syndrome - Pipeline by Crinetics Pharmaceuticals, Inc., H1 2015
Polycystic Ovarian Syndrome - Pipeline by EffRx Pharmaceuticals S.A., H1 2015
Polycystic Ovarian Syndrome - Pipeline by Euroscreen S.A., H1 2015
Polycystic Ovarian Syndrome - Pipeline by Merck KGaA, H1 2015
Polycystic Ovarian Syndrome - Pipeline by Neurocrine Biosciences, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Polycystic Ovarian Syndrome Therapeutics - Recent Pipeline Updates, H1 2015
Polycystic Ovarian Syndrome - Dormant Projects, H1 2015
List of Figures
Number of Products under Development for Polycystic Ovarian Syndrome, H1 2015
Number of Products under Development for Polycystic Ovarian Syndrome - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report